Generate:Biomedicines to begin global phase 3 studies of GB-0895, a long-acting anti-TSLP antibody for severe asthma engineered with AI: Somerville, Massachusetts Tuesday, Decembe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback